Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $27,640,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. This represents a 5.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The stock was sold at an average price of $34.00, for a total transaction of $21,276,622.00.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $35.13 on Friday. Roivant Sciences Ltd. has a 1 year low of $10.70 and a 1 year high of $35.90. The firm has a 50-day moving average of $30.12 and a 200 day moving average of $27.21. The stock has a market cap of $25.27 billion, a P/E ratio of -58.55 and a beta of 1.11.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. During the same quarter last year, the firm earned ($0.29) earnings per share. Research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently added to or reduced their stakes in the company. TD Asset Management Inc lifted its holdings in shares of Roivant Sciences by 94.7% during the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after purchasing an additional 153,800 shares in the last quarter. HighVista Strategies LLC boosted its position in shares of Roivant Sciences by 61.4% during the third quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock valued at $1,496,000 after buying an additional 37,590 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in Roivant Sciences by 790.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after buying an additional 2,052,693 shares in the last quarter. Neo Ivy Capital Management increased its holdings in Roivant Sciences by 229.6% in the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock worth $3,592,000 after buying an additional 165,362 shares in the last quarter. Finally, Capricorn Fund Managers Ltd raised its position in Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after buying an additional 247,000 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ROIV shares. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen boosted their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Guggenheim increased their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Citigroup raised their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Finally, Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.